Aquestive Therapeutics (AQST) Payables: 2017-2025
Historic Payables for Aquestive Therapeutics (AQST) over the last 8 years, with Sep 2025 value amounting to $10.9 million.
- Aquestive Therapeutics' Payables rose 43.49% to $10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.4 million, marking a year-over-year increase of 38.71%. This contributed to the annual value of $10.3 million for FY2024, which is 15.25% up from last year.
- Per Aquestive Therapeutics' latest filing, its Payables stood at $10.9 million for Q3 2025, which was down 9.09% from $12.0 million recorded in Q2 2025.
- Aquestive Therapeutics' 5-year Payables high stood at $12.4 million for Q1 2023, and its period low was $5.7 million during Q2 2024.
- For the 3-year period, Aquestive Therapeutics' Payables averaged around $10.1 million, with its median value being $10.5 million (2024).
- Per our database at Business Quant, Aquestive Therapeutics' Payables plummeted by 59.21% in 2021 and then soared by 109.81% in 2025.
- Quarterly analysis of 5 years shows Aquestive Therapeutics' Payables stood at $8.3 million in 2021, then rose by 19.63% to $9.9 million in 2022, then dropped by 10.26% to $8.9 million in 2023, then increased by 15.25% to $10.3 million in 2024, then skyrocketed by 43.49% to $10.9 million in 2025.
- Its Payables was $10.9 million in Q3 2025, compared to $12.0 million in Q2 2025 and $12.3 million in Q1 2025.